Tumor-specific CD8+ T cells exhibited a significant increase in Ki-67 expression on day 7, whereas virus-specific CD8+ T cells did not, indicating the specificity of PD-1 therapy for expanding tumor-reactive CD8+ T cells (33). The gene discussed is PDCD1; the disease is neoplasm.